%0 Case Reports
%T Precision oncology strategy in cetuximab-resistant ERRFI1-mutant colon cancer: case report of disease progression on afatinib.
%A Kuznetsova O
%A Lebedeva A
%A Kavun A
%A Belova E
%A Fedyanin M
%A Mileyko V
%A Ivanov M
%A Nosov D
%J Am J Transl Res
%V 15
%N 9
%D 2023
%M 37854204
%F 3.94
%X Despite the existence of effective first and second line therapy options for patients with colorectal cancer, heavily treated patients have limited additional therapies. Genomic profiling is a promising tool for guiding subsequent treatment selection. Here, we describe the results of treating a colorectal cancer patient with molecularly-matched therapy based on the results of genomic profiling. The patient received a combination of afatinib and bevacizumab due to the presence of ERRFI1 variant. To our knowledge, this is the first report on the effect of EGFR inhibitors in patients with ERRFI1-altered RAS/BRAF wild-type colorectal adenocarcinoma.